Background
Cedecea are gram negative, oxidase negative bacilli that include 5 species. This genus was designated by the Centers for Disease Control (CDC) in 1981 as a separate genus in the Enterobacteriaceae family. The Cedecea bacteria are closely related to the Serratia bacteria but do not hydrolyze DNA or gelatin [1] . In the medical literature there are very few reports that describe infections such as pneumonia, soft tissues infections, urinary tract infections and sepsis, which were caused by different species of the Cedecea genus such as C. neteri and C. lapagei. In most cases, these infections appeared in immunocompromised patients [2] [3] [4] [5] [6] [7] .
In the present case report we describe a third case of sepsis which caused by Cedecea davisae in a patient with chronic renal disease stage V and to present a review of all literature documented cases which were caused by C. davisae.
Case Report
A 77 year-old female patient with chronic kidney disease stage V, a history of diabetic nephropathy and hypertension, on hemodialysis treatment since 2008, was admitted to our Nephrology Department for a routine hemodialysis treatment on May 2012.
During the hemodialysis treatment, the patient started to complain of chills, fever, nausea and leg cramps. Later, non-hemorrhagic diarrhea and vomiting appeared lasting a few days.
On physical examination, the patient was hemodynamically stable with a blood pressure of 200/90 mm Hg and fever of 39.5°C. Chest X-ray revealed no evidence of inflammatory infiltration, 6,800 leukocytes per mcL on cell blood count test, with 90% neutrophils. Urine culture, 2 sets of blood culture and culture from the Permacat catheter tip were drawn and antibiotic treatment was started with vancomycin and gentamicin. Urine culture was negative. However, all the blood cultures (Bactec FX system, BD, USA) and the catheter tip culture were positive, with gram negative bacilli growth on blood, chocolate and MacConkey agars. Later, these bacilli were defined as Cedecea davisae by an automatic microbial identification system, VITEK 2 (BioMérieux, Durham, NC) and by means of the molecular biology method of 16S RNA. In addition, an antibiogram test was performed in the Kirby-Bauer method (disk diffusion antibiotic sensitivity testing) in which we found that the bacterium was sensitive to amikacin, ceftazidim, ciprofloxacin, gentamicin, meropenem, trinethoprim/sulfa and levofloxacin, and resistant to ampicillin, ampicillin/sulbactam and cefazolin. Therefore the treatment was replaced with ciprofloxacin and ceftazidim. During the antibiotic therapy, no additional fever rises were seen and follow-up cultures that were drawn were sterile. The patient got released from the hospital after 4 hospitalization days in a stable state with a recommendation for further treatment with ciprofloxacin for 10 days (Table 1) . DM -diabetes mellitus; HTN -hypertension; CHF -congestive heart failure; COPD -chronic obstructive pulmonary disease; DIC -disseminated intravascular coagulation; AML -acute myeloid leukemia.
Discussion
In 1981, a gram negative, oxidase negative, fermentative bacillus formerly known as enteric group 15 of the family Entrobacteriacaeae, was designated as a new and a separate genus. This genus includes 5 different species]1[. In the medical literature there are a few documented cases in which these bacteria were isolated from various clinical specimens including sputum, urine, soft tissues and blood. Most of the isolates came from infections in immunocompromised patients. To the best of our knowledge, five cases (not including our report) of Cedecea bacteremia were reported so far. The first case was reported in 1982. Three out of these five Cedecea bacteremia cases were caused by C. davisae and the rest by C. lapagei and C.neteri [2, 7] .
Cedecea infections and particularly C. davisae infections can be difficult to treat due to the antibiotic resistance of the bacterium [5, 8] . The previously described cases reported microbial resistance to cephalothin, cefuroxime, ceftazidim, ampicillin, tetracycline, cefoxitin, piperacillin, nitrofurntoin and ciprofloxacin. In our report we described another case of C. davisae bacteremia in a patient with chronic renal disease stage V that was successfully treated with ceftazidim and ciprofloxacin.
Conclusions
In this case report, we report for the first time on C. davisae isolation from Permacath catheter tip culture and on microbial resistance to ampicillin/sulbactam and cefazolin. Therefore we propose to consider treating C. davisae bacteremia with a combined antibiotic treatment until getting laboratory results for antibiotic-sensitivity tests.
